We are targeting a portfolio of autoimmune diseases with our engineered T cell therapy candidates. Our lead Chimeric Antigen Receptor T cell for Autoimmunity (CARTA) candidate, CABA-201, is being advanced in the RESETTM (REstoring SElf-Tolerance) Phase 1/2 clinical trials in systemic lupus erythematosus, myositis, systemic sclerosis and generalized myasthenia gravis, with potential application in a broad portfolio of other autoimmune diseases in rheumatology, neurology, and other therapeutic areas.
1CABA-201 is being evaluated in separate clinical trials for myositis, SLE, SSc & gMG.
2Additional CAART pipeline candidates include PLA2R-CAART in preclinical stage for PLA2R membranous nephropathy, DSG3/1-CAART in discovery stage for mucocutaneous pemphigus vulgaris & 2 undisclosed targets in discovery stage.
3Currently being evaluated in a Phase 1 trial.